Advances & Updates

Post Updates

Aug 14

PNOC FOUNDATION, A LEADING NON-PROFIT DEDICATED TO ACCELERATING TREATMENTS FOR THE DEADLIEST CHILDHOOD BRAIN CANCERS, APPLAUDS THE U.S. FDA APPROVAL OF ONC201 (DORDAVIPRONE, NOW MODEYSO™) AS THE FIRST AND ONLY TREATMENT FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA

ONC201 FDA approval for diffuse midline glioma - August 14, 2025

Media Release  Pre-clinical studies by PNOC’s DMG Working Group members contributed...

Read more

Oct 09

Pediatric Neuro-Oncology Consortium Partnership Receives Prestigious ARPA-H Multi-Million Dollar Grant for Groundbreaking RADIANT Project, to Rapidly Advance Treatments for Children With Brain Tumors

FOR IMMEDIATE RELEASE SAN FRANCISCO, October 9, 2024 – The Pediatric Neuro-Oncology...

Read more

Nov 20

PNOC PUBLICATION!

PNOC001: Phase II Study of Everolimus For Recurrent or Progressive Low-Grade Gliomas in Children

...

Read more

Feb 03

Machine learning to identify LGG subgroups

Our Imaging working group looks at how an unsupervised machine learning approach could review and...

Read more

Connect with PNOC

Collaboration is a key part of PNOC’s values and our success. We collaborate with individuals, hospitals, research institutions, patients and families – with anyone. Contact us if you have an idea or question, or if you would like to learn more about collaborating with us.